Glossary
7-hydroxymitragynine (7-OH)
Updated:
A minor alkaloid of Mitragyna speciosa that DEA says makes up less than 2 percent of the plant's total alkaloid content. Concentrated or converted 7-OH products are the subject of 2025 FDA warning letters and a 2026 DEA notice proposing Schedule I above 1 mg per gram or milliliter or below a 100-to-1 mitragynine ratio.
In the leaf, 7-hydroxymitragynine is a trace component: DEA's July 2026 notice states it "makes up less than two percent of the total alkaloid content or occurs in trace amount" in Mitragyna speciosa (91 FR 40917). On the extract reports linked from this store's lab-results pages it is reported as not detected at a 0.025 ppm limit of quantitation.
The products regulators call "7-OH" are different: tablets and drink mixes in which 7-OH has been concentrated or produced by converting mitragynine, at 14 to 59 mg per tablet. FDA describes them as distinct from the plant and sent seven warning letters to their marketers in 2025 (FDA, Hiding in plain sight). The October 2026 notice proposes Schedule I for 7-OH above 1 mg per gram or milliliter, or where mitragynine is less than 100 times the 7-OH by mass, with an order possible on or after 2026-11-13 (91 FR 65370).
State lines are tighter in places: 0.4 mg per gram in Kentucky, 0.5 mg per gram and 1 mg per serving in Georgia, 1 mg per serving in Virginia and Maryland, 0.5 mg per container in Mississippi, and 2 percent of the alkaloid fraction in eight states.
Sources
- 91 FR 40917, notice of intent (July 6, 2026) Federal Register via GovInfo (accessed 2026-10-20)
- 91 FR 65370, notice of intent (October 14, 2026) Federal Register via GovInfo (accessed 2026-10-20)
- Hiding in plain sight: 7-OH products U.S. Food and Drug Administration (accessed 2026-10-20)